AgomAb Therapeutics N.V. American Shares
AGMB | NASDAQ
$7.49
-$0.46 (-5.79%)
At close: Oct 30, 2026, 4:00 PM ET
$7.49
$0.00 (0.00%)
After-hours:
Oct 30, 2026, 7:30 PM ET
Fiscal Quarter Period Ending | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 | Q4 2024 Dec 31, 2024 |
|---|---|---|---|
Revenue | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a |
Operating Income | -16.53M | -15.36M | -11.81M |
Interest Income | 581K | 173K | 471K |
Pretax Income | -17.4M | -18.28M | -11.73M |
Net Income | -17.4M | -18.28M | -11.73M |
Selling & General & Admin | 3.25M | 2.64M | 1.38M |
Research & Development | 13.86M | 12.99M | 10.73M |
Other Expenses | -589K | -274K | -298K |
Operating Expenses | 16.53M | 15.36M | 11.81M |
Interest Expense | n/a | 124K | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a |
Cost & Expenses | 16.53M | 15.36M | 11.81M |
Income Tax Expense | n/a | n/a | 4K |
Shares Outstanding (Basic) | 48.74M | 42.49M | 36.24M |
Shares Outstanding (Diluted) | 48.74M | 42.49M | 36.24M |
EPS (Basic) | -0.36 | -0.43 | -0.32 |
EPS (Diluted) | -0.36 | -0.43 | -0.32 |
EBITDA | -17.62M | -18.05M | -11.8M |
EBIT | -17.54M | -18.15M | -11.88M |
Depreciation & Amortization | -83K | 107K | 85K |
Add to Watchlist
Select watchlists to add or remove AGMB